Zydus Cadila's US arm Nesher Pharma gets 11 observations from USFDA
Nesher Pharma, a 100 per cent subsidiary of Zydus Pharmaceuticals USA, saw USFDA inspection at its two facilities
 "Zydus Cadila's US arm Nesher Pharma gets 11 observations from USFDA")
premium
Facilities of Cadila Healthcare Ltd. (Zydus Cadila)'s US arm, Nesher Pharmaceuticals (USA) LLC, have received 11 observations from the US Food & Drug Administration (USFDA), the Indian pharma company stated on Monday.
Nesher Pharma, a 100 per cent subsidiary of Zydus Pharmaceuticals USA, saw USFDA inspection at its two facilities located at St. Louis, Missouri from May 13 to May 31, 2019. Apart from three observations at one facility and eight at another, Nesher Pharma also bagged a 'voluntary action indicated' (VAI) recommendation from the regulator, as per Cadila Healthcare's filing on BSE.
Nesher Pharma, a 100 per cent subsidiary of Zydus Pharmaceuticals USA, saw USFDA inspection at its two facilities located at St. Louis, Missouri from May 13 to May 31, 2019. Apart from three observations at one facility and eight at another, Nesher Pharma also bagged a 'voluntary action indicated' (VAI) recommendation from the regulator, as per Cadila Healthcare's filing on BSE.
"This was a product specific pre-approval inspection with general cGMP and there were no Data Integrity (DI) related observations. The company is confident of addressing these observations and responding to the USFDA at the earliest," Cadila Healthcare stated in its BSE filing on Monday.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%